OR WAIT 15 SECS
Novartis Pharma and Ono Pharmaceutical have signed an agreement to codevelop and co market...
Novartis Pharma and Ono Pharmaceutical have signed an agreement to codevelop and co market the world's first transdermal patch for the treatment of Alzheimer's disease in Japan. The rivastigmine patch, which is currently undergoing Phase II clinical trials in Japan, is expected to be more convenient; for example, caregivers can easily confirm the administration of the drug.
Exelon (rivastigmine) is already sold as an oral capsule or liquid in more than 70 countries outside Japan. The patch will offer patients a new choice for the treatment of Alzheimer's disease, particularly those who experience difficulty swallowing or are uncooperative in taking their medication.
Alzheimer's disease is a progressive, degenerative disease that alters the brain, causing impaired memory, thinking and behaviour. Affecting approximately 10 million people worldwide (1 million people in Japan) and 2–6% of those over 65 years of age, it is the most common form of dementia and the third leading cause of death in this age group behind cardiovascular disease and cancer.